Paper25908682
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K and 19 others. Clin Infect Dis, 2015. Cited by 131 papers, by iCite.
Cite this record
ConductScience Library. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Papers, record 25908682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25908682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-HIV Agents | Major topic |
| Bone Density | Major topic |
| Chemoprevention | Major topic |
| Emtricitabine | Major topic |
| HIV Infections | Major topic |
| Tenofovir | Major topic |
| Absorptiometry, Photon | |
| Administration, Oral | |
| Adolescent | |
| Adult | |
| Cytoplasm | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Placebos | |
| Plasma | |
| Young Adult |
Source PubMed
Grants9
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| UM1 AI069476 | NIAID NIH HHS | United States | UM1AI069476 | PubMed and NIH | NIH RePORTER |
| U01 AI84735 | NIAID NIH HHS | United States | U01AI084735 | PubMed and NIH | NIH RePORTER |
| U01 AI084735 | NIAID NIH HHS | United States | U01AI084735 | PubMed and NIH | NIH RePORTER |
| R01 AI118575 | NIAID NIH HHS | United States | R01AI118575 | PubMed | NIH RePORTER |
| R03 AI120819 | NIAID NIH HHS | United States | R03AI120819 | PubMed and NIH | NIH RePORTER |
| UM1 AI069496 | NIAID NIH HHS | United States | UM1AI069496 | PubMed and NIH | NIH RePORTER |
| U01AI64002 | NIAID NIH HHS | United States | U01AI064002 | PubMed and NIH | NIH RePORTER |
| UL1 TR000004 | NCATS NIH HHS | United States | UL1TR000004 | PubMed and NIH | NIH RePORTER |
| U01 AI064002 | NIAID NIH HHS | United States | U01AI064002 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00458393 | Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 25908681 | Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis. | https://conductscience.org/library/papers/25908681 |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22096407 | Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. | HIV AIDS (Auckl) | 2011 | https://conductscience.org/library/papers/22096407 | PubMed |
| 2 | 19842973 | Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. | Clin Infect Dis | 2009 | https://conductscience.org/library/papers/19842973 | PubMed |
| 3 | 19398921 | A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. | J Acquir Immune Defic Syndr | 2009 | https://conductscience.org/library/papers/19398921 | PubMed |
| 4 | 19512937 | Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. | J Acquir Immune Defic Syndr | 2009 | https://conductscience.org/library/papers/19512937 | PubMed |
| 5 | 21522014 | Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. | J Acquir Immune Defic Syndr | 2011 | https://conductscience.org/library/papers/21522014 | PubMed |
| 6 | 22784038 | Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22784038 | PubMed |
| 7 | 22784037 | Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22784037 | PubMed |
| 8 | 24625530 | Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. | PLoS One | 2014 | https://conductscience.org/library/papers/24625530 | PubMed |
| 9 | 9351170 | Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. | Stat Med | 1997 | https://conductscience.org/library/papers/9351170 | PubMed |
| 10 | 20683316 | Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. | AIDS | 2010 | https://conductscience.org/library/papers/20683316 | PubMed |
| 11 | 22972843 | Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. | Sci Transl Med | 2012 | https://conductscience.org/library/papers/22972843 | PubMed |
| 12 | 25296097 | Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy. | J Acquir Immune Defic Syndr | 2015 | https://conductscience.org/library/papers/25296097 | PubMed |
| 13 | 19874178 | Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. | J Infect Dis | 2009 | https://conductscience.org/library/papers/19874178 | PubMed |
| 14 | 17053350 | A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. | AIDS | 2006 | https://conductscience.org/library/papers/17053350 | PubMed |
| 15 | 15293701 | Prevention and management of osteoporosis. | World Health Organ Tech Rep Ser | 2003 | https://conductscience.org/library/papers/15293701 | PubMed |
| 16 | 23148289 | Low bone mineral density, regardless of HIV status, in men who have sex with men. | J Infect Dis | 2013 | https://conductscience.org/library/papers/23148289 | PubMed |
| 17 | 25170938 | The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. | PLoS One | 2014 | https://conductscience.org/library/papers/25170938 | PubMed |
| 18 | 18573931 | Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18573931 | PubMed |
| 19 | 22819139 | Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. | J Clin Densitom | 2012 | https://conductscience.org/library/papers/22819139 | PubMed |
| 20 | 18793764 | International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. | Bone | 2008 | https://conductscience.org/library/papers/18793764 | PubMed |
Cited by87
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 131 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42579882 | HIV Pre-Exposure Prophylaxis Use Among South Asian Sexual Minority Men in the United States: Pilot Web-Based Survey Study. | JMIR Form Res | 2026 | https://conductscience.org/library/papers/42579882 | PubMed |
| 42141514 | Renal function in African women receiving tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV during pregnancy and postpartum: A postpartum safety analysis in the CAP016 randomized control trial. | HIV Med | 2026 | https://conductscience.org/library/papers/42141514 | PubMed |
| 41891184 | Association between plasma concentrations of integrase strand transfer inhibitors and body weight gain in women with HIV. | AIDS | 2026 | https://conductscience.org/library/papers/41891184 | PubMed |
| 41797349 | Bone Health in People Living with HIV: From Pathophysiology to Practical Management. | Infect Chemother | 2026 | https://conductscience.org/library/papers/41797349 | PubMed |
| 41040064 | Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025. | Euro Surveill | 2025 | https://conductscience.org/library/papers/41040064 | PubMed |
| 40632108 | Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy. | J Pediatric Infect Dis Soc | 2025 | https://conductscience.org/library/papers/40632108 | PubMed |
| 40071257 | Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status. | Infez Med | 2025 | https://conductscience.org/library/papers/40071257 | PubMed |
| 39528419 | In-utero exposure to tenofovir-containing pre-exposure prophylaxis and bone mineral content in HIV-unexposed infants in South Africa. | J Int AIDS Soc | 2024 | https://conductscience.org/library/papers/39528419 | PubMed |
| 38484128 | Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. | Clin Infect Dis | 2024 | https://conductscience.org/library/papers/38484128 | PubMed |
| 38399361 | Effects of Tenofovir Disoproxil Fumarate on Bone Quality beyond Bone Density-A Scoping Review of the Literature. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38399361 | PubMed |
| 37971137 | Cytogenetic changes in oral mucosa cells from individuals submitted to oral human immunodeficiency virus pre-exposure prophylaxis use. | Rev Assoc Med Bras (1992) | 2023 | https://conductscience.org/library/papers/37971137 | PubMed |
| 37861643 | Pre-exposure prophylaxis for prevention of HIV infection. | Singapore Med J | 2023 | https://conductscience.org/library/papers/37861643 | PubMed |
| 35687192 | Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). | AIDS Behav | 2022 | https://conductscience.org/library/papers/35687192 | PubMed |
| 35355890 | Navigating Human Immunodeficiency Virus and Primary Care Concerns Specific to the Transgender and Gender-Nonbinary Population. | Open Forum Infect Dis | 2022 | https://conductscience.org/library/papers/35355890 | PubMed |
| 34992111 | CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women. | BMJ Open | 2022 | https://conductscience.org/library/papers/34992111 | PubMed |
| 34791296 | Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/34791296 | PubMed |
| 34697493 | HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. | Nat Rev Urol | 2022 | https://conductscience.org/library/papers/34697493 | PubMed |
| 34482350 | Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. | AIDS | 2021 | https://conductscience.org/library/papers/34482350 | PubMed |
| 34482349 | The combined effects of age and HIV on the anatomic distribution of cortical and cancellous bone in the femoral neck among men and women. | AIDS | 2021 | https://conductscience.org/library/papers/34482349 | PubMed |
| 34075504 | Pre-Exposure Prophylaxis (PrEP) for HIV Infection in Cisgender and Transgender Women in the U.S.: A Narrative Review of the Literature. | Arch Sex Behav | 2021 | https://conductscience.org/library/papers/34075504 | PubMed |
Drugs3
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| TENOFOVIR DISOPROXIL FUMARATE | CHEMBL1486 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1486 | ChEMBL |
| EMTRICITABINE, (+/-)- | CHEMBL161381 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL161381 | ChEMBL |
| EMTRICITABINE | CHEMBL885 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL885 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25908682
GET https://conductscience.org/api/papers/v1/25908682/references?page=2